Compare Recursion Pharmaceuticals Inc (RXRX) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs State Street Technology Select Sector SPDR ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $4.41 (market cap $2.14B), while State Street Technology Select Sector SPDR ETF trades at $198.9 (market cap $132.55B). The key difference: State Street Technology Select Sector SPDR ETF is far larger — about 61.9× Recursion Pharmaceuticals Inc's market cap, and State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 23 Days and State Street Technology Select Sector SPDR ETF for 50 Days on average.
| RXRX | XLK | |
|---|---|---|
Market Cap | $2.14B | $132.55B |
Volume | 30,789,535 | 9,063,135 |
Sector | Health | Sector/Thematic |
52-Week High | $6.79 | $202.00 |
52-Week Low | $2.84 | $127.49 |
Typical Hold Time | 23 Days | 50 Days |
Enterprise Value | $1.66B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
XLK, the Technology Select Sector SPDR ETF, trades at $198.78, down 1.3% over the past day amid broader tech sector pressure. The technical outlook remains bullish based on moving averages, with neutral oscillators suggesting consolidation near the pivot point of $199. Recent news highlights AI-driven momentum in software stocks and ETF concentration concerns, while a future dividend of $0.22 is scheduled for September 2026.
The ETF's outlook is supported by strong AI investment themes and large-cap tech earnings resilience, but risks include interest rate sensitivity and high concentration in semiconductor holdings. Analyst sentiment is mixed, with some favoring alternative tech ETFs for better diversification. Key resistance lies at $201, with support at $196.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
